About Us
Research and Development
Established in 1999, we strongly value the importance of nurturing a working culture of innovation.
-
LifeTech Scientific Corporation Announces 2025 Annual Results: Steady Revenue Growth with Adjusted Net Profit Increasing 24.9%2026 / 03 / 31
-
LifeTech Scientific Corporation Announces 2025 Interim Results: Core Business Demonstrated Resilience, Domestic and Overseas Sales Both IncreasedLifeTech Scientific Corporation, a medical device company specializing in minimally invasive interventional solutions for cardio-cerebrovascular and peripheral vascular diseases, today announced its unaudited consolidated results for the six months ended 30 June 2025.2025 / 08 / 29
-
LifeTech Scientific Corporation Announced 2024 Annual Results：Revenue Exceeded RMB1.3 billion, and International Business Increased by 26%LifeTech Scientific Corporation, a?company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiariesannounced?the audited consolidated results for the year ended 31 December 2024.2025 / 03 / 28
-
LifeTech Scientific Corporation Announced 2023 Annual Results：International Business Achieved a Robust Growth, Innovation at the Core to Drive the Solid DevelopmentLifeTech Scientific Corporation (the “Company” or “Lifetech”, Stock code: 1302.HK), a?company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries announced?the audited consolidated results for the year ended 31 December 2023.2024 / 04 / 02
-
LifeTech Scientific Corporation Announced 2024 Interim Results：International Business Increased by 30%, Net Profit Margin Attributable to Owners of the Company Reached 35.8%LifeTech Scientific Corporation (the “Company” or “LifeTech”, Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiaries (the “Group”) announced the consolidated results for the six months ended 30 June 2024 (the “Reporting Period”).2024 / 08 / 30
Becoming a globally-recognized, trustworthy and innovative interventional medical device enterprise
